Gene · 25937
Papers2,228
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,228
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hippo signaling impairs alveolar epithelial regeneration in pulmonary fibrosis. | Elife | 2023 | 37166104 | PubTator, text mining | PubMed |
| Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations. | Cancer Med | 2023 | 37165917 | PubTator, text mining | PubMed |
| Epstein-Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ. | Proc Natl Acad Sci U S A | 2023 | 37155846 | PubTator, text mining | PubMed |
| Bibliometric and visualization analysis of kidney repair associated with acute kidney injury from 2002 to 2022. | Front Pharmacol | 2023 | 37153766 | PubTator, text mining | PubMed |
| Case report: Multiple brain intravascular papillary endothelial hyperplasia: incidence, diagnostic challenges, and management approach. | Front Neurol | 2023 | 37153668 | PubTator, text mining | PubMed |
| Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression. | J Exp Clin Cancer Res | 2023 | 37150829 | PubTator, text mining | PubMed |
| MST1 downregulates TAZ tumor suppressor protein in multiple myeloma and is a potential therapeutic target. | Exp Hematol | 2023 | 37137439 | PubTator, text mining | PubMed |
| Epithelioid hemangioendothelioma of the distal lower extremity and the role of radiotherapy: A report of two cases. | Rare Tumors | 2023 | 37124838 | PubTator, text mining | PubMed |
| Reverse effect of Semaphorin-3F on rituximab resistance in diffuse large B-cell lymphoma via the Hippo pathway. | Chin Med J (Engl) | 2023 | 37114652 | PubTator, text mining | PubMed |
| Pituitary Tumorigenesis-Implications for Management. | Medicina (Kaunas) | 2023 | 37109772 | PubTator, text mining | PubMed |
| Lipid-Sensing Receptor FFAR4 Modulates Pulmonary Epithelial Homeostasis following Immunogenic Exposures Independently of the FFAR4 Ligand Docosahexaenoic Acid (DHA). | Int J Mol Sci | 2023 | 37108233 | PubTator, text mining | PubMed |
| Potential effective diagnostic biomarker in patients with primary and metastatic small intestinal neuroendocrine tumors. | Front Genet | 2023 | 37091799 | PubTator, text mining | PubMed |
| Simvastatin Attenuates Glucocorticoid-Induced Human Trabecular Meshwork Cell Dysfunction via YAP/TAZ Inactivation. | Curr Eye Res | 2023 | 37083467 | PubTator, text mining | PubMed |
| The expanding universe of NUTM1 fusions in pediatric cancer. | Clin Transl Sci | 2023 | 37082775 | PubTator, text mining | PubMed |
| Mice Deficient in TAZ (Wwtr1) Demonstrate Clinical Features of Late-Onset Fuchs' Endothelial Corneal Dystrophy. | Invest Ophthalmol Vis Sci | 2023 | 37074694 | PubTator, text mining | PubMed |
| Congress Report on the Second World Congress of Global Scar Society with Scar Academy and Japan Scar Workshop. | Plast Reconstr Surg Glob Open | 2023 | 37073255 | PubTator, text mining | PubMed |
| Transplanted human intestinal organoids: a resource for modeling human intestinal development. | Development | 2023 | 37070767 | PubTator, text mining | PubMed |
| The lysophosphatidic acid-regulated signal transduction network in ovarian cancer cells and its role in actomyosin dynamics, cell migration and entosis. | Theranostics | 2023 | 37064875 | PubTator, text mining | PubMed |
| Pathological angiogenesis: mechanisms and therapeutic strategies. | Angiogenesis | 2023 | 37060495 | PubTator, text mining | PubMed |
| Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. | Theranostics | 2023 | 37056572 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25937/papers?page=16